Navigation Links
Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
Date:5/4/2009

DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain.

The product incorporates Circ Pharma's proprietary drug delivery technology enabling once daily dosing. Circ's technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption immediately prior to the waking hours and the subsequent maintenance of efficacious drug levels for the remainder of the waking hours. Circ has successfully completed Phase I testing on the product.

Currently the worldwide market for pain treatments is worth about US$26 billion and is forecast to grow to about $31 billion by 2011. In the US and Europe the moderate to severe pain market was estimated to be worth about $6.7 billion in 2007. The tramadol market in the US and Europe was worth about $1.1 billion in 2008.

Circ Pharma intends to seek a licensing partner for worldwide commercial distribution of the product.

The agreement with Elan provides that Elan support the continued formulation and manufacturing activities required to seek regulatory approval for this product in the United States and elsewhere. "Elan's extensive experience, know-how and technology for the development and manufacture of scheduled products for the US market will ensure that we can quickly and efficiently complete all the development and clinical activities required for Chrono Tramadol" said Circ Pharma's Chief Technical Officer, Margot Foynes.

About Circ Pharma

Circ Pharma is a specialty pharmaceutical product development company whose mission is to develop differentiated novel formulations of products based on existing drugs that provide incremental patient benefit. Circ Pharma has a strong intellectual property portfolio and technology in the areas of targeted and chronotherapeutic drug delivery and a broad clinical stage pipeline of novel product opportunities in a number of indications including cardiovascular and pain indications. http://www.circpharma.com

    Further Information:

    Media Contact
    Mr. Ray Gordon, Gordon MRM
    Telephone: +353-1-6650450
    E-mail: ray@gordonmrm.ie



'/>"/>
SOURCE Circ Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
2. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2009 Results
11. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):